3 Dividend Stocks Worth Buying Now?
Thanks to surging stock prices over the past two years, dividend yields on major stock indices have fallen to fairly low levels. The S&P 500, for instance, currently carries an average yield of just 1.3%.
The mature companies in the Dow Jones Industrial Average fare a bit better, and some of them offer yields that exceed the S&P 500 several times over. » Read more about: 3 Dividend Stocks Worth Buying Now? »
Read More
Is Tesla a Buy Under $200?
In the investing world, Jim Cramer grabs a lot of headlines, but other less well-known names arguably deserve substantially more attention. Oliver Kell is one such name. He’s got the distinguished title of US Champion Trader with a 941.1% return in 2020.
He’s also got quite a knack for finding the hottest stocks in the market,
» Read more about: Is Tesla a Buy Under $200? »
Read More
Market Commentary: Valentine’s Day Massacre Begins Now
For investors who are only familiar with stock investing, the options market can seem like a great unknown. That market is so large that it can sometimes act like the tail wagging the dog.
As we approach the monthly expiration of options in February, the risks to the market grow. That fact is well understood by one analyst,
» Read more about: Market Commentary: Valentine’s Day Massacre Begins Now »
Read More
14 Billion Reasons To Avoid Fast Growth
It seems every generation needs to learn the same lesson the hard way. In 2000, when technology stocks were flying high but fundamentals failed to justify the valuations, the fear of missing out on big gains caused many to chase higher highs and regret it.
More recently, a similar type of investment, draped in narrative and shy on fundamentals,
» Read more about: 14 Billion Reasons To Avoid Fast Growth »
Read More
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
AI Bets and Buffett’s Seal of Approval, Is This a Bet on a Cashless Future?
There is something inherently attractive about buying a stock and holding it for a long time. Stable don’t just have strong balance sheets that can weather rough markets but they often pay dividends, which account for as much as 95% of total returns over the past century according to research by Wharton Professor Jeremy Siegel.
» Read more about: AI Bets and Buffett’s Seal of Approval, Is This a Bet on a Cashless Future? »
Read MoreThe Spotlight
1 Growth Stock Down Over 85% to Buy Now
Roku Inc. (NASDAQ: ROKU) seems like a stock to run from at first glance. With shares down by over 85% since the heady days of 2021 and profits still to be delivered, it’s hard to make a strong case for the company as a good investment.
But a deeper dive reveals some compelling reasons to pay attention to this former high flyer.
» Read more about: 1 Growth Stock Down Over 85% to Buy Now »
Read MoreThe Daily
The Best High-Yield Dividend ETF to Invest $1,000 in Right Now
If you have $1,000 available to invest and are looking to buy a high-yield dividend exchange-traded fund (ETF), you need to tread carefully.
» Read more about: The Best High-Yield Dividend ETF to Invest $1,000 in Right Now »